Last reviewed · How we verify
Cyclic peptide Fertiline
Fertiline is a cyclic peptide that modulates reproductive hormone signaling to enhance fertility.
Fertiline is a cyclic peptide that modulates reproductive hormone signaling to enhance fertility. Used for Infertility (ovulatory dysfunction or male factor infertility).
At a glance
| Generic name | Cyclic peptide Fertiline |
|---|---|
| Also known as | cFEE |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | GnRH agonist or reproductive hormone modulator |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health / Fertility |
| Phase | Phase 3 |
Mechanism of action
As a cyclic peptide therapeutic, Fertiline likely acts on gonadotropin-releasing hormone (GnRH) pathways or related reproductive endocrine targets to improve ovulation or spermatogenesis. The cyclic peptide structure provides enhanced stability and receptor selectivity compared to linear peptides, potentially improving bioavailability and clinical efficacy in fertility applications.
Approved indications
- Infertility (ovulatory dysfunction or male factor infertility)
Common side effects
- Headache
- Hot flashes
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclic peptide Fertiline CI brief — competitive landscape report
- Cyclic peptide Fertiline updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI